Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82

• Status: Completed
• Trial end date: 2018-07-02
• Target enrollment: 0
• Participant gender: All

Summary

In this this investigation, 15 subjects with a high probability of cardiac sarcoidosis based on clinical criteria and abnormal cardiac FDG uptake on initial, clinically indicted FDG PET study will be considered for this study. The study will test the following Aims:

Aim 1. Effect of FDG incubation time on visual and quantitative interpretation of FDG uptake.

Changes in incubation time can affect imaging target:background ratios and study sensitivity/specificity. For the study-directed exam, all patients will undergo sequential cardiacfocused FDG-PET imaging at 90 and 120 minutes after injection of FDG. Imaging variables will be evaluated as below.

Aim 2. Reproducibility of FDG and Rb82 PET findings on sequential imaging. It is unknown whether FDG-positive imaging findings in cardiac sarcoidosis are reproducible. All patients will undergo study-directed FDG-PET/CT with MPI imaging within approximately 2 weeks from initial clinical scan.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Treatments: Fluorodeoxyglucose F18

Criteria

Inclusion Criteria:

Symptoms

• Palpitations/presyncope/syncope

• Heart failure symptoms Signs

• Abnormal ECG or Holter

• RBBB, LBBB, LAFB

• Abnormal Q waves in ≥2 leads

• 1st degree AVB > 240 msec, 2nd/3rd deg. AVB

• Frequent PVCs

• VT (sustained/non-sustained)

• LVEF < 50%

• Cardiac Regional Wall Motion Abnormality

Exclusion Criteria:

• Low likelihood of CS/Other explanation for symptoms

• Inability to consent

• Pregnancy